Zoledronat OSTEO Labatec, solution pour perfusion

7680622570025 CH-62257 Infusionslösung
Zoledronat OSTEO Labatec, solution pour perfusion
Zoledronat OSTEO Labatec, solution pour perfusion
Zoledronat OSTEO Labatec, solution pour perfusion
1 / 3
google

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Infusionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
08/10/2024
Summary of Product Characteristics
Français
08/10/2024
Summary of Product Characteristics
Italien
08/10/2024

Detailed composition

Substance Quantity Type Category
(N/A)
5.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance WIZUS
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
7.21 MG Substance HBESI

Reimbursement information

Public price
CHF 220.65
Specialties list
Yes
Generic
Yes

Reimbursement limitation

SL addition date: 01/01/2023

Authorization holder

Labatec Pharma SA

1217 Meyrin

Authorization information

Swissmedic authorization number
62257
Drug name
Zoledronat OSTEO Labatec, solution pour perfusion
Galenic form
LSMP
ATC Code
M05BA08
Authorization status
Z
Dispensing category
B
First authorization
29/03/2012
Authorization expiration date
31/12/9999
IT Number
07.99.0.
Domain
Human medicine
Field of application
Morbus Paget, postmenopausale Osteoporose

Package details

Description (FR)
ZOLEDRONAT Osteo Labatec sol perf 5 mg/100ml
Description (DE)
ZOLEDRONAT Osteo Labatec Inf Lös 5 mg/100ml
Market launch
29/03/2012
Narcotic (BTM)
No

Original drug

Aclasta, Infusionslösung
GTIN: 7680573630014
CHF 254.45
View original

Other package sizes (1)

None
None None
GTIN: None
Not in V1